Pediatric Hospitalist/Nocturnist - Los Angeles Area
City of Hope
August 1, 2018
Full Time - Experienced
We are seeking a board certified pediatrician to care for pediatric hematology/oncology inpatients. This position features:
In-house, overnight and weekend management of 10-18 inpatient pediatric hematology, oncology, and hematopoietic cell transplantation (HCT) patients on the pediatric floor and occasionally in our ICU
Back up from the covering pediatric hem/onc attending and PICU attending
Attend all code blues within the 200+ bed facility
Management of pediatric patients presenting in our Evaluation and Treatment Center (ETC), as well as taking phone calls from patients/parents and outside hospitals about our patients
160 hours per month, divided between weekday 15.5 hour shifts and weekend 24 hour shifts. Typical monthly breakdown is 7 weekday shifts and 2 weekend shifts, with some flexibility month-to-month
Opportunity for moonlighting additional shifts is available most months
No procedures required
Excellent base salary and benefits
Work out of just one hospital
Excellent opportunity for candidates interested in being exposed to challenging pediatric hematology and oncology patients
Must be board eligible/certified in pediatrics. Ideal candidate will have completed a pediatric hematology/oncology fellowship.
Experience caring for inpatient pediatric patients at high levels of acuity is preferred.
Internal Number: Peds Nocturnist
About City of Hope
City of Hope delivers scientific miracles that make lives whole again. A world-leader in cancer research, treatment and prevention, doctors partner with scientists to transform laboratory breakthroughs into treatments that outsmart cancer, as well as diabetes and other life-threatening diseases.
Located at the foot of the San Gabriel Mountains, 20 miles from Los Angeles, City of Hope is designated as a comprehensive cancer center, the highest recognition bestowed by the National Cancer Institute. City of Hope has been ranked as one of “America’s Best Hospitals” in cancer by
U.S. News & World Report for 13 years.